AA genotype linked to reduced severity, but not occurrence, of TD; no association seen for rs210133 with TD occurrence, severity
TUESDAY, June 25, 2024 (HealthDay News) — For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not associated with occurrence, according to a study recently published in Human Psychopharmacology: Clinical & Experimental.
Ruoyu Wang, from the Centre for Addiction and Mental Health in Toronto, and colleagues tested SNPs rs13194504 and rs210133 for the association with the occurrence and severity of TD among 172 patients with schizophrenia who were recruited for four studies at three clinical sites in Canada and the United States.
The researchers found that there was an association for the rs13194504 AA genotype with reduced severity for TD, as measured by the Abnormal Involuntary Movement Scale (AIMS), but not for occurrence of TD. No significant association was seen for rs210133 with either TD occurrence or AIMS scores.
“Our results suggest that the SNP rs13194504 AA genotype may be associated with decreased severity of TD, thus pointing to a potential protective effect against TD,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Brain Abnormalities Identified in Children at Risk for Schizophrenia 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Dose-Dependent Link Seen for Clomiphene Citrate, Adverse Perinatal Outcomes 
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors 
